---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000163"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:52:11.642010+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q3 revenue $781M (+102% YoY); net income of $215M vs loss of $558M last year

## Summary
- Global product sales up 70% to $595M; BRUKINSA sales $358M (+130%) led by US launch momentum.
- Net income $215M vs net loss $558M in Q3 2022; operating loss improved by $304M YoY.
- Total revenue $781M (+102%); US revenue $398M, China $288M, Europe $86M.
- Gross margin improved to 83.8% from 78.1% on higher-mix BRUKINSA and lower tislelizumab costs.
- Cash $3.2B; TEVIMBRA approved in EU, US BLA accepted for ESCC with PDUFA July 2024.

## SEC filing metadata
- accession: 0001651308-23-000163
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/0001651308-23-000163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/bgne-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000163
- JSON: https://secwatch.observer/filing/0001651308-23-000163.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000163.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported the three months ended September 30, 2023 results: revenue total revenue of $781 million, net income Net Income ... $215.4 million.
  - Period: the three months ended September 30, 2023
  - Revenue: total revenue of $781 million
  - Net income: Net Income ... $215.4 million
  - Result: reported results
  source text: Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates • Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage • Global sales of BRUKINSA
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/0001651308-23-000163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.